These data indicates a different combination of EGFR, CDKN2A, PTEN CNVs, and TP53, ATRX mutation status reflect a unique genetic composition of glioma patients at different age groups and IDH mutation status. This evidence concerns the gene ATRX and central nervous system cancer.